Check out our recent news
may 2023
Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001
feb 2023
Pioneering Delix Therapeutics Study Published in 'Science' Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity
feb 2023
Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability
sept 2022
Taking the tripping out of psychedelic medicine
sept 2022
Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association
sept 2022
Delix Therapeutics Expands World-Class Team with First Head of R&D
sept 2022
Ketamine, psilocybin and ecstasy are coming to the medicine cabinet
sept 2022
Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up
sept 2022
Nature Biotechnology’s academic spinouts 2021
aug 2022
Get Ready for the Magic Mushroom Pill
july 2022
Taking the Magic Out of Magic Mushrooms
july 2022
Accessibility Is Key for the Psychedelic Revolution
mar 2022
Drug companies are investing big in psychedelics, but can they engineer out the trip?
jan 2022
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
jan 2022
Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank
dec 2021
Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders
oct 2021
Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board
oct 2021
Delix Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2021
sept 2021
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
aug 2021